LP
SRPT icon

LMR Partners’s Sarepta Therapeutics SRPT Stock Holding History

LMR Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Sell
1,392,400
-30,400
-2% -$575K 0.09% 193
2026
Q1 		$31M Sell
1,422,800
-30,000
-2% -$581K 0.07% 151
2025
Q4 		$31.3M Buy
1,452,800
+70,500
+5% +$1.49M 0.06% 145
2025
Q3 		$26.6M Buy
+1,382,300
New +$24.6M 0.12% 140
2024
Q4 		– Sell
-87,700
Closed -$11M – 1576
2024
Q3 		$11M Sell
87,700
-58,400
-40% -$8.07M 0.09% 204
2024
Q2 		$23.1M Buy
146,100
+11,700
+9% +$1.5M 0.2% 102
2024
Q1 		$17.4M Sell
134,400
-100,600
-43% -$12.3M 0.18% 117
2023
Q4 		$22.7M Sell
235,000
-132,200
-36% -$12.7M 0.26% 92
2023
Q3 		$44.5M Buy
367,200
+28,200
+8% +$3.19M 0.5% 39
2023
Q2 		$38.8M Buy
+339,000
New +$43.7M 0.43% 55

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LMR Partners's SRPT Position: Q2 2026 in Review

LMR Partners reduced its Sarepta Therapeutics (SRPT) stake by 99% in Q2 2026, selling an estimated $272K and leaving 138 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1474.

LMR Partners first reported a position in SRPT in Q2 2018 and has held it in 19 quarters since. The position peaked at $12.8M in Q2 2018. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • LMR Partners held 138 shares of Sarepta Therapeutics worth $2.48K as of Q2 2026.
  • LMR Partners sold 14,386 Sarepta Therapeutics shares in Q2 2026, an estimated $272K.
  • Sarepta Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1474 holding.
  • LMR Partners first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • LMR Partners's Sarepta Therapeutics position peaked at $12.8M in Q2 2018.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.